In a new op-ed published in Roll Call, PIPC Chairman Tony Coelho weighs in on the debate of using comparative effectiveness research (CER) to control medical spending. Chairman Coehlo emphasizes that "proposals for Medicare and private payers to use CER are understandable, but concerning. Understandable because the challenge of rising costs is real, and policy-makers naturally reach for familiar policy tools. Concerning because it would pull CER away from individualized patient decisions and back towards centralized payer decisions. The end result would be limited choice of treatments based on one-size-fits-all determinations of 'value' for the average patient."